Alpha 2.0
Login Register
» Articles » PMID: 37915929

Contemporary Secondary Prevention in Survivors of ST-elevation Myocardial Infarction with and Without Chronic Kidney Disease: a Retrospective Analysis

Overview
Journal Clin Kidney J
Publisher Oxford University Press
Specialty Nephrology
Date 2023 Nov 2
PMID 37915929
Authors
Christiane Engelbertz
Jannik Feld
Lena Makowski
Stefan A Lange
Christian Gunster
Patrik Droge
Thomas Ruhnke
Joachim Gerss
Holger Reinecke
Jeanette Koppe
Affiliations
Soon will be listed here.
Abstract

Background: Survivors of myocardial infarction have an elevated risk of long-term mortality. We sought to evaluate guideline-directed medical treatment and its impact on long-term mortality in survivors of ST-elevation myocardial infarction (STEMI) according to their chronic kidney disease (CKD) stage.

Methods: Using German health insurance claims data, 157 663 hospitalized survivors of STEMI were identified. Regarding different CKD stages, we retrospectively analysed the filled prescriptions of platelet inhibitors (PAI)/oral anticoagulation, statins, beta-blocker and angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor antagonists (ACE-I/AT1-A) and their association with long-term mortality.

Results: Prescription rates for all four guideline-directed drugs were highest in patients without or with mild CKD and lowest in patients on dialysis. They dropped from 73.4% to 39.2% in patients without CKD and from 47.1% to 29% in patients on dialysis within the 5-year follow-up period. Mortality rates were dramatically increased in patients with CKD compared with patients without CKD (5-year mortality: no CKD, 16.7%; CKD stage 3, 47.1%; CKD stage 5d, 69.7%). Filled prescriptions of at least one drug class [one drug: hazard ratio (HR) 0.70, 95% confidence interval (95% CI) 0.66-0.74; four drugs: HR 0.28, 95% CI 0.27-0.30;  < .001 for both] as well as the distinct drug classes (statins: HR 0.55, 95% CI 0.54-0.56; ACE-I/AT1-A: HR 0.68, 95% CI 0.67-0.70; beta-blocker: HR 0.87, 95% CI 0.85-0.90; PAI/oral anticoagulation: HR 0.97, 95% CI 0.95-1.00; all  < .05) improved long-term mortality.

Conclusions: An improved long-term guideline-recommended drug therapy after STEMI regardless of renal impairment might lead to beneficial effects on long-term mortality.

References
1.
Tomasevic D, El Khoury C, Subtil F, Dubien P, Bochaton T, Serre P . Effect of Optimal Medical Therapy at Discharge in Patients With Reperfused ST-Segment Elevation Myocardial Infarction on 1-Year Mortality (from the Regional RESCUe Registry). Am J Cardiol. 2018; 121(4):403-409. DOI: 10.1016/j.amjcard.2017.11.002. View
2.
Jernberg T, Johanson P, Held C, Svennblad B, Lindback J, Wallentin L . Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA. 2011; 305(16):1677-84. DOI: 10.1001/jama.2011.522. View
3.
Schmucker J, Fach A, Osteresch R, Marin L, Retzlaff T, Ruhle S . Temporal trends in treatment strategies and clinical outcomes among patients with advanced chronic kidney disease and ST-elevation myocardial infarctions: results from the Bremen STEMI registry. BMC Cardiovasc Disord. 2022; 22(1):142. PMC: 8976374. DOI: 10.1186/s12872-022-02573-1. View
4.
Bansilal S, Castellano J, Garrido E, Wei H, Freeman A, Spettell C . Assessing the Impact of Medication Adherence on Long-Term Cardiovascular Outcomes. J Am Coll Cardiol. 2016; 68(8):789-801. DOI: 10.1016/j.jacc.2016.06.005. View
5.
Gitsels L, Kulinskaya E, Steel N . Survival prospects after acute myocardial infarction in the UK: a matched cohort study 1987-2011. BMJ Open. 2017; 7(1):e013570. PMC: 5278246. DOI: 10.1136/bmjopen-2016-013570. View